Septerna Inc (SEPN)

$12.61 -0.09 (-0.71%)
Market Cap 533.24M
Revenue (ttm) 1.08M
Net Income (ttm) -71.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,648.15%
Debt to Equity Ratio 0.00
Volume 134,895
Avg Vol 312,430
Day's Range N/A - N/A
Shares Out 44.59M
Stochastic %K 97%
Beta N/A
Analysts Strong Sell
Price Target $24.25

Company Profile

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; a...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 338 3533
Address:
250 East Grand Avenue, South San Francisco, United States
habesha_kingtchalla
habesha_kingtchalla Aug. 25 at 4:08 PM
$SEPN
0 · Reply
_Julia
_Julia Aug. 24 at 3:57 PM
$SEPN What's up guys. I founded this board. Hope you are doing well. Good luck 🤞
1 · Reply
DCRMIA
DCRMIA Aug. 22 at 11:08 AM
$SEPN "H.C. Wainwright Reiterates Buy Rating on Septerna Inc" https://www.investing.com/news/pro/hc-wainwright-maintains-septerna-at-buy-with-a-price-target-of-2600-4206519
0 · Reply
SocioCobb
SocioCobb Aug. 14 at 12:56 AM
$SEPN 5 month 2 banger
0 · Reply
kuwshlavi
kuwshlavi Aug. 13 at 3:46 PM
$SEPN 👀👀
0 · Reply
DCRMIA
DCRMIA Aug. 13 at 10:35 AM
I am quite optimistic about $SEPN 🚀🚀
1 · Reply
kuwshlavi
kuwshlavi Aug. 12 at 2:42 PM
$SEPN should be too much money to keep it under $12 we shall see though
0 · Reply
Copperhead_Road
Copperhead_Road Aug. 12 at 2:12 PM
$SEPN take this down to $10 today
0 · Reply
kuwshlavi
kuwshlavi Aug. 12 at 1:46 PM
$SEPN not doing a pr after closing the Novo deal led to this.. smfh now just a spot on the watchlist
1 · Reply
d_risk
d_risk Aug. 12 at 1:14 AM
$SEPN - Septerna, Inc. - 10Q - Updated Risk Factors SEPN flags heightened risks from U.S. budget constraints, FDA staffing cuts, regulatory delays, new tariffs, trade tensions, inflation, and warns that healthcare reforms, tax law changes, and shifting federal policies could materially impact operations and financials. #Healthcare #FederalPolicy #Inflation #TradeTensions #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/SEPN/10-Q/2025-08-11
0 · Reply
Latest News on SEPN
Septerna to Participate in Upcoming Investor Conferences

Aug 27, 2025, 8:00 AM EDT - 7 hours ago

Septerna to Participate in Upcoming Investor Conferences

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

Aug 21, 2025, 8:00 AM EDT - 6 days ago

Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Aug 11, 2025, 4:01 PM EDT - 15 days ago

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

Jun 23, 2025, 2:30 PM EDT - 2 months ago

Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

Septerna to Present at Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 3 months ago

Septerna to Present at Jefferies Global Healthcare Conference

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

May 16, 2025, 4:32 PM EDT - 3 months ago

Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash

May 16, 2025, 11:50 AM EDT - 3 months ago

Septerna: Deal With Novo Nordisk Is A Game Changer While It Still Trades Well Below Net Cash

NVO

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

May 15, 2025, 4:01 PM EDT - 3 months ago

Septerna Highlights Business Progress and Reports First Quarter 2025 Financial Results

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

May 14, 2025, 9:43 AM EDT - 3 months ago

Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs

NVO

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

May 14, 2025, 7:31 AM EDT - 3 months ago

Novo Nordisk and Septerna Collaborate on Oral Medicines for Obesity and Other Diseases

NVO

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

May 14, 2025, 7:04 AM EDT - 3 months ago

Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments

NVO

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

May 14, 2025, 6:59 AM EDT - 3 months ago

Novo Nordisk A/S: Septerna and Novo Nordisk to collaborate on oral small molecule medicines for obesity and other cardiometabolic diseases

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

Mar 31, 2025, 2:34 PM EDT - 5 months ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CRVO CVS GERN LLY NVO

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 27, 2025, 8:00 AM EDT - 5 months ago

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm

Mar 19, 2025, 10:32 AM EDT - 5 months ago

SEPN Investors Have Opportunity to Join Septerna, Inc. Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Shareholders to Reach Out

Mar 6, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Shareholders to Learn More About the Investigation

Mar 5, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Shareholders to Learn More About the Investigation

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Mar 4, 2025, 10:00 AM EST - 6 months ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Shareholders to Inquire about Securities Investigation

Mar 3, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Shareholders to Inquire about Securities Investigation

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 2, 2025, 10:00 AM EST - 6 months ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Septerna, Inc. (SEPN) And Encourages Investors to Connect

Feb 28, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Septerna, Inc. (SEPN) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Stockholders to Inquire about Securities Investigation

Feb 27, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Investors to Learn More About the Investigation

Feb 26, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Investors to Learn More About the Investigation

Septerna to Present at TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:00 AM EST - 6 months ago

Septerna to Present at TD Cowen 45th Annual Health Care Conference

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Feb 24, 2025, 10:00 AM EST - 6 months ago

Septerna, Inc. (SEPN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Stockholders to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Septerna, Inc. (SEPN) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Investors to Inquire about Securities Investigation

Feb 21, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Septerna, Inc. (SEPN) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Investors to Reach Out

Feb 20, 2025, 10:00 AM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Investors to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Stockholders to Reach Out

Feb 19, 2025, 2:00 PM EST - 6 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Septerna, Inc. (SEPN) And Encourages Stockholders to Reach Out

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Feb 18, 2025, 4:15 PM EST - 6 months ago

Septerna, Inc. Investors: Company Investigated by the Portnoy Law Firm

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Feb 18, 2025, 8:00 AM EST - 6 months ago

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 18, 2024, 8:00 AM EST - 9 months ago

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Nov 20, 2024, 7:00 AM EST - 10 months ago

Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

Nov 19, 2024, 2:10 PM EST - 10 months ago

Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

Oct 30, 2024, 4:41 PM EDT - 10 months ago

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

Oct 26, 2024, 1:30 AM EDT - 10 months ago

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

INGM LBGJ PRB ROLR SNYR

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Oct 25, 2024, 12:25 PM EDT - 10 months ago

Septerna valued at $970 million as shares rise nearly 31% in Nasdaq debut

Septerna Prices Upsized Initial Public Offering

Oct 24, 2024, 9:47 PM EDT - 10 months ago

Septerna Prices Upsized Initial Public Offering

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

Oct 24, 2024, 8:11 AM EDT - 10 months ago

Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO

Biotech Septerna aims to raise up to $186 million in US IPO

Oct 21, 2024, 6:26 AM EDT - 11 months ago

Biotech Septerna aims to raise up to $186 million in US IPO

Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline

Oct 7, 2024, 11:36 AM EDT - 11 months ago

Septerna Pursues $100 Million IPO For Endocrine And Metabolic Drug Pipeline

habesha_kingtchalla
habesha_kingtchalla Aug. 25 at 4:08 PM
$SEPN
0 · Reply
_Julia
_Julia Aug. 24 at 3:57 PM
$SEPN What's up guys. I founded this board. Hope you are doing well. Good luck 🤞
1 · Reply
DCRMIA
DCRMIA Aug. 22 at 11:08 AM
$SEPN "H.C. Wainwright Reiterates Buy Rating on Septerna Inc" https://www.investing.com/news/pro/hc-wainwright-maintains-septerna-at-buy-with-a-price-target-of-2600-4206519
0 · Reply
SocioCobb
SocioCobb Aug. 14 at 12:56 AM
$SEPN 5 month 2 banger
0 · Reply
kuwshlavi
kuwshlavi Aug. 13 at 3:46 PM
$SEPN 👀👀
0 · Reply
DCRMIA
DCRMIA Aug. 13 at 10:35 AM
I am quite optimistic about $SEPN 🚀🚀
1 · Reply
kuwshlavi
kuwshlavi Aug. 12 at 2:42 PM
$SEPN should be too much money to keep it under $12 we shall see though
0 · Reply
Copperhead_Road
Copperhead_Road Aug. 12 at 2:12 PM
$SEPN take this down to $10 today
0 · Reply
kuwshlavi
kuwshlavi Aug. 12 at 1:46 PM
$SEPN not doing a pr after closing the Novo deal led to this.. smfh now just a spot on the watchlist
1 · Reply
d_risk
d_risk Aug. 12 at 1:14 AM
$SEPN - Septerna, Inc. - 10Q - Updated Risk Factors SEPN flags heightened risks from U.S. budget constraints, FDA staffing cuts, regulatory delays, new tariffs, trade tensions, inflation, and warns that healthcare reforms, tax law changes, and shifting federal policies could materially impact operations and financials. #Healthcare #FederalPolicy #Inflation #TradeTensions #RegulatoryRisk 🟢 Added 🟠 Removed https://d-risk.ai/SEPN/10-Q/2025-08-11
0 · Reply
Copperhead_Road
Copperhead_Road Aug. 11 at 11:58 PM
$SEPN this should start off tomorrow gapped down like back in February. It is unnatural for this to have not gone down at all with a 98.25% miss on earnings
1 · Reply
Deekay1
Deekay1 Aug. 11 at 9:06 PM
$SEPN There must be like 2 retail persons invested in this! LOL
0 · Reply
Deekay1
Deekay1 Aug. 11 at 8:50 PM
$SEPN WTF what a Miss on earnings...
0 · Reply
Copperhead_Road
Copperhead_Road Aug. 11 at 8:38 PM
$SEPN missed on quarterly sales by 98.25%! Sales were only $119K versus an expected estimate of $6.8 million. This should have tanked 50% after hours.
1 · Reply
_MANDALORIAN_
_MANDALORIAN_ Aug. 8 at 10:10 PM
$SEPN oh no it was doing so well.. whyyyyyyy? Novo price tied up? Whatever algo shmockery.. its not doing it justice eitherway. Lets say, test 10.60 then shoot back 14.80? Deal?
0 · Reply
kuwshlavi
kuwshlavi Aug. 4 at 2:09 PM
$SEPN back to 14 this week
0 · Reply
OnlyTimeWillTell888
OnlyTimeWillTell888 Jul. 28 at 4:06 PM
$SEPN Wrong way!
0 · Reply
OnlyTimeWillTell888
OnlyTimeWillTell888 Jul. 28 at 1:14 PM
$SEPN Maybe this week?
0 · Reply
rst1016
rst1016 Jul. 25 at 8:00 PM
$SEPN I was a seller at 10.50. Congrats here
1 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 25 at 12:09 AM
$SEPN Outstanding article that hits the mark on SEPN's current state. So if you want to refresh your SEPN insights or learn about SEPN from scratch, this is a must read. https://beyondspx.com/article/septerna-unlocking-gpcr-potential-with-a-differentiated-platform-and-novo-nordisk-partnership-nasdaq-sepn
0 · Reply
BillRayValentine
BillRayValentine Jul. 24 at 7:13 PM
$SEPN Nasty Work !! LFG!!! Mucho problems above $13.85 for bears 🐨
1 · Reply
DCRMIA
DCRMIA Jul. 24 at 5:38 PM
$SEPN Very bullish📈
0 · Reply